Enables retinoic acid binding activity. Involved in retinoic acid biosynthetic process. Predicted to be located in endoplasmic reticulum and nucleoplasm. Predicted to be active in cytosol and nucleus. Orthologous to human CRABP2 (cellular retinoic acid binding protein 2); PARTICIPATES IN retinoic acid metabolic pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 4-tert-Octylphenol; 9-cis-retinoic acid.
[Tretinoin co-treated with alpha-Tocopherol] results in increased expression of CRABP2 mRNA and [Tretinoin co-treated with alpha-Tocopherol] results in increased expression of CRABP2 protein
[Estradiol co-treated with TGFB1 protein] results in decreased expression of CRABP2 mRNA and [Progesterone co-treated with Estradiol] results in decreased expression of CRABP2 mRNA
[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of CRABP2 mRNA and Tetrachlorodibenzodioxin inhibits the reaction [Tretinoin results in increased expression of CRABP2 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
[Disulfiram binds to Copper] which results in decreased expression of CRABP2 mRNA and [NSC 689534 binds to Copper] which results in decreased expression of CRABP2 mRNA
[Disulfiram binds to Copper] which results in decreased expression of CRABP2 mRNA and [NSC 689534 binds to Copper] which results in decreased expression of CRABP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA